SEC Form 4 · accession 0001193125-26-396894
Bolt Biotherapeutics, Inc. · BOLT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Grant Yonehiro
Officer — Chief Operating Officer
Period of report
Sep 16, 2026
Accepted (ET)
Sep 21, 2026 · 6:05 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001641281
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 16, 2026 | S | 1,417 | $3.774 | D | 29,028 | D | |
| Common StockF2 | Sep 17, 2026 | S | 4,909 | $3.3183 | D | 24,119 | D | |
| Common StockF3 | Sep 18, 2026 | S | 6,850 | $3.2364 | D | 17,269 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.60 to $4.14. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.22 to $3.67. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F3Represents weighted average sales price. These shares were sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units granted on October 22, 2025. The shares were sold at prices ranging from $3.15 to $3.41. The Reporting Person will provide upon request, to the Securities and Exchange Commission (the "SEC"), the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.